Breath testing is becoming an important diagnostic method to evaluate many disease states.
In the light of rising healthcare costs, is important to develop a simple non-invasive tool to potentially identify pediatric patients who need endoscopy for suspected inflammatory bowel disease (IBD).
Dr Alkhouri and colleagues from Ohio, USA analyzed exhaled volatile organic compounds (VOCs), and investigated the presence of a unique breath patterns to differentiate paediatric patients with (IBD) from healthy controls.
A cross-sectional, single-center study included pediatric IBD patients and healthy controls.
|3 specific volatile organic compounds had excellent accuracy for predicting the presence of IBD|
|Alimentary Pharmacology & Therapeutics|
The diagnosis of IBD was confirmed by endoscopic, histological and radiographic data.
The research team collected exhaled breath and analyzed using a selective ion flow tube mass spectroscopy (SIFT-MS) to identify new markers or patterns of IBD.
The team included 117 patients in the study.
Linear discriminant analysis and principle component analysis of mass scanning ion peak data demonstrated 21 pre-selected VOCs correctly classify patients with IBD or as healthy controls.
The team showed that 3 specific VOCs had excellent accuracy for predicting the presence of IBD with an area under the curve (AUC) of 0.96.
The team found no significant difference in VOCs between patients with Crohn's disease or ulcerative colitis, and no significant correlation was seen with disease activity.
Dr Alkhouri's team concludes, "These pilot data support the hypothesis that a unique breathprint potentially exists for pediatric IBD in the exhaled metabolome."